Metron Nutraceuticals, L.L.C. v. Thomas

2022 Ohio 79
Ohio Court of Appeals·Decided January 13, 2022·No. 110280·Published·Cited by 5 cases

Opinion

COURT OF APPEALS OF OHIO

EIGHTH APPELLATE DISTRICT COUNTY OF CUYAHOGA

METRON NUTRACEUTICALS, L.L.C., :

Plaintiff-Appellee, :

No. 110280

v. :

CLAYTON THOMAS, ET AL., :

Defendants-Appellants. :

JOURNAL ENTRY AND OPINION

JUDGMENT: AFFIRMED

RELEASED AND JOURNALIZED: January 13, 2022

Civil Appeal from the Cuyahoga County Court of Common Pleas Case No. CV-16-859345

Appearances:

Lewis Brisbois Bisgaard and Smith, L.L.P., Ryan K. Rubin, Daniel Leister, and Gregory P. Amend, for appellee.

Luftman, Heck & Associates, L.L.P., and Matthew L.

Alden, for appellants.

KATHLEEN ANN KEOUGH, J.:

Defendant-appellant Clayton Thomas (“Thomas”) appeals from the trial court’s judgment that granted the motion of plaintiff-appellee Metron Nutraceuticals, L.L.C. (“Metron”) to show cause why Thomas should not be held in contempt and ordered him to pay Metron $222,360 in damages and $33,179 for its attorney fees incurred in litigating the motion. Finding no merit to Thomas’s appeal, we affirm.

I. Substantive and Procedural Background In 2016, Metron filed suit against Thomas and his company, Personalized Healthcare Solutions, L.L.C. (“PHS”). The complaint arose out of Metron and Thomas’s business dealings.

The complaint alleged that Metron’s president, Dr. Nikolaos Tsirikos-

Karapanos, had invented a patent-pending process to make water-soluble hydrolyzed clinoptilolite fragments, a hydrolyzed zeolite that can be consumed to help the body eliminate toxins. The complaint further alleged that in 2014, Dr. Tsirikos-Karapanos, Thomas, and other investors founded Metron with the intention of selling the hydrolyzed zeolite under the name CytoDetox. Metron’s operating agreement prohibited any member from engaging in other business ventures that utilize zeolites or chemical solutions or formulas containing zeolites. Thomas also signed a nonsolicitation, confidentiality, and noncompete agreement. Nevertheless, in August 2015, without the consent or knowledge of Metron, Thomas formed PHS, a zeolite distribution company, in direct competition with Metron. Then, again without Metron’s knowledge or authorization, Thomas contacted Metron’s packaging department and ordered it to ship all of Metron’s remaining CytoDetox product, or 2,616 bottles, to Thomas’s residence in Tacoma, Washington. Despite demands, Thomas refused to return the CytoDetox to Metron.

Metron’s complaint asserted claims against Thomas and PHS for breach of fiduciary duty, breach of the duties of loyalty and care, breach of contract, conversion and/or civil theft, violation of the Uniform Trade Secrets Act, fraud in the inducement, tortious interference with contract and business relations, and unjust enrichment. The complaint also sought temporary and permanent injunctive relief.

After a hearing, the trial court granted a preliminary injunction. It found that the evidence presented at the hearing

demonstrated that not only are Defendants engaging in competitive businesses in violation of contracts and agreements with Metron, but Plaintiff presented evidence of Defendants’ internet-based websites and podcasts and radio publications/broadcasts that Metron opined were not authorized and amount to misinforming the public. Further, based on Plaintiff’s evidence, Defendants are selling product either directly stolen from Metron or manufactured by way of violating Metron’s trade secrets, patents, and confidentiality agreements. The evidence also indicated that Defendants have forged and misrepresented contracts, and Defendants have misrepresented the product, resulting in direct harm to Plaintiff. These acts also violate Thomas’s fiduciary duties to Metron, as he is a shareholder.

Subsequently, after a hearing, the trial court granted default judgment to Metron. The trial court’s judgment ordered Thomas to forfeit his 15.99 percent share in Metron and pay compensatory damages and ordered permanent injunctive relief against Thomas and PHS.

Three times thereafter, the trial court found Thomas in civil contempt of court for failing to comply with the trial court’s injunction. Each time, the court had ordered various sanctions and purge conditions, none of with which Thomas complied. When Thomas failed to appear at a purge hearing despite an order to do so, the court found him in criminal contempt and issued a warrant for his arrest.

Thomas and PHS then filed a motion for relief from judgment. At the hearing on the defendants’ motion, the court also heard argument regarding Thomas’s contempt. The trial court found that Thomas was still in contempt, had made no effort whatsoever to purge himself of contempt, and continued to engage in activities from which he had been enjoined. The court ordered Thomas remanded to the Cuyahoga County Jail to serve three days’ imprisonment.

Subsequently, after the court denied the defendants’ motion for relief from judgment, in an effort to bring finality to the matter, the parties filed a joint motion for relief from judgment requesting that the trial court enter an agreed judgment. The trial court granted the motion and entered the agreed judgment, which among other things, ordered that Thomas and PHS were to “immediately” return to Metron all remaining bottles of CytoDetox in Thomas’s possession or under his control.

In July 2020, Metron filed a motion for Thomas to show cause as to why he should not be held in contempt for failing to comply with the agreed judgment. The trial court conducted an evidentiary hearing, after which both parties filed post-hearing briefs. In its post-hearing brief, Metron requested its attorney fees incurred in litigating the motion.

In its journal entry granting Metron’s motion to show cause (which the trial court concluded was “essentially a motion to enforce a settlement agreement”), the trial court found that although it had ordered Thomas and PHS three times to return the 2,616 bottles of CytoDetox to Metron (i.e., in the preliminary injunction, the permanent injunction, and the agreed judgment entry), “none (zero) of the 2,616 bottles were returned.” The court found that “because Mr. Thomas failed to return any of the CytoDetox bottles, in violation of the court’s orders and his own agreement,” Metron was entitled to $222,360 in damages, which the court determined was the fair market value of the unreturned bottles. The court also found that Thomas and PHS had violated the agreed judgment in other ways, but that Metron had not proved any damages regarding those violations.

With respect to attorney fees, the court found that Metron’s request for $31,609 in attorney fees and $1,570 for litigation support incurred “due to Mr. Thomas’s violation of the settlement agreement” was “reasonable based on the experience of counsel and on the rate charged within this area of law in Cleveland, Ohio.” Accordingly, it awarded Metron $33,179 in attorney fees. This appeal followed.

II. Law and Analysis A. Damages Award In his first assignment of error, Thomas contends that the trial court abused its discretion in awarding $222,360 to Metron for his failure to comply with paragraph 9 of the agreed judgment entry, which ordered him to “immediately” return the 2,616 bottles of CytoDetox to Metron. Thomas contends that the trial court’s award of $222,360 was unreasonable and against the manifest weight of the evidence because the evidence at the hearing about whether the bottles had been returned and the value of the bottles was disputed.

Free access — add to your briefcase to read the full text and ask questions with AI

Metron Nutraceuticals, L.L.C. v. Thomas, 2022 Ohio 79 (Ohio Ct. App. 2022).

2022 Ohio 79 (Metron Nutraceuticals, L.L.C. v. Thomas) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related

Shelly Co. v. N.E.S. Corp.
Ohio Court of Appeals, 2026
Citywide RX, L.L.C. v. Providence Healthcare Mgt., Inc.
2026 Ohio 1377 (Ohio Court of Appeals, 2026)
Williams v. Hung
2024 Ohio 5093 (Ohio Court of Appeals, 2024)
Alami v. Khalid
2024 Ohio 2456 (Ohio Court of Appeals, 2024)
Taylor v. BASF Catalysts, L.L.C.
2023 Ohio 1136 (Ohio Court of Appeals, 2023)
Eagle Realty Invests., Inc. v. Dumon
2022 Ohio 4106 (Ohio Court of Appeals, 2022)
WSB Rehab. Servs. Inc. v. Cent. Accounting Sys. Inc.
2022 Ohio 2160 (Ohio Court of Appeals, 2022)